Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2025-04-22 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
财通证券股份有限公司关于江西新赣江药业股份有限公司2024年度募集资金存放及使用情况的核查报告
Regulatory Filings
2025-04-22 Chinese
会计师事务所对资金占用的专项审核意见
Regulatory Filings
2025-04-22 Chinese
2024年度内部控制审计报告
Regulatory Filings
2025-04-22 Chinese
2025年度董事、监事、高级管理人员薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the 2025 remuneration scheme for the company's directors, supervisors, and senior management. It details the salary standards, approval procedures, and related meeting resolutions. It does not contain financial statements or performance data but focuses on compensation plans and governance matters. This fits the definition of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors.
2025-04-22 Chinese
董事会审计委员会2024年履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a report on the 2024 performance of the Board Audit Committee of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the committee's activities, meetings, evaluations of financial reports, and audit supervision during the year 2024. It does not contain full financial statements or detailed financial data but rather a summary and evaluation of audit-related activities and committee work. This type of document is a report on audit committee activities and oversight, which fits the category of Audit Report / Information (AR) rather than a full Annual Report or Interim Report. The document length is 1733 characters, which is relatively short but contains substantive content about audit committee duties and evaluations, not just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2024
2025-04-22 Chinese
2024年度审计报告
Regulatory Filings
2025-04-22 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.